Employers and patients shifting on GLP‑1s

Employers used to treat weight-loss drugs like an edge case in the pharmacy budget. Two new surveys suggest they are now redesigning benefits around them, while patients are also becoming less fixed on one class of drugs. (PR Newswire: ) (PR Newswire: ) Glucagon-like peptide-1 drugs copy a gut hormone that helps regulate appetite and blood sugar. In practice, they make many patients feel full sooner, eat less, and lose weight, which is why they moved from diabetes care into obesity treatment. (World Health Organization: ) (JAMA Internal Medicine: ) That shift happened fast. Peterson-KFF notes that prescriptions for weight loss rose sharply after Wegovy was approved in 2021 and Zepbound was approved in 2023, turning what had been a niche category into a mainstream benefits question for employers. (Peterson-KFF Health System Tracker: ) (U.S. Food and Drug Administration: ) The basic employer problem is simple. These drugs can improve health for a large group of workers, but they are expensive, often used for long periods, and can push up pharmacy spending much faster than a company expected. (Peterson-KFF Health System Tracker: ) (Business Group on Health: ) KFF’s 2025 Employer Health Benefits Survey found that larger employers increased coverage of glucagon-like peptide-1 drugs for weight loss, even as annual family premiums for employer coverage climbed 6 percent to $26,993. That is the backdrop for every human resources team now trying to decide whether access is a recruiting tool, a medical necessity, or a runaway cost center. (KFF: ) The 9amHealth survey released on April 7, 2026, shows how far employee expectations have moved. In its nationally representative survey of more than 1,000 working-age U.S. adults conducted in December 2025, 49 percent said they were using glucagon-like peptide-1 drugs, more than double the 2023 share. (PR Newswire: ) The same survey found that glucagon-like peptide-1 coverage now ranks among the top three most valued workplace benefits for more than 40 percent of respondents. It also found that 30 percent of workers would change jobs to gain or keep access, which turns a pharmacy benefit into a retention issue. (PR Newswire: ) Demand still looks larger than current coverage. Among employees without employer coverage, 93 percent told 9amHealth they would take a glucagon-like peptide-1 drug if their employer covered it, while more than half of respondents said cost was the main barrier to starting or staying on treatment. (PR Newswire: ) The patient side of the market is shifting too, but in a different direction. Phenomix Sciences said on April 7, 2026, that many patients who had already used obesity medications knew very little about non-glucagon-like peptide-1 options until someone explained them. (PR Newswire: ) In that Phenomix survey, 57 percent said they were completely unaware of, or unfamiliar with, comparable non-glucagon-like peptide-1 options such as Qsymia. Qsymia itself is not new; the Food and Drug Administration lists its initial U.S. approval in 2012, which shows how much the public conversation has narrowed around the newer injectable drugs. (PR Newswire: ) (U.S. Food and Drug Administration label: ) Once patients heard about alternatives, opinions moved. Phenomix found that 68 percent changed their views after learning more, including 25 percent who became more open to non-glucagon-like peptide-1 options, 25 percent who wanted to discuss all options with a clinician, and 18 percent who became less interested in glucagon-like peptide-1 drugs. (PR Newswire: ) That creates an awkward mismatch for benefit design. Employers are being pulled toward broader coverage because workers increasingly expect these drugs, while patient education may push some people toward a wider menu of treatments than the headline brands that dominate demand. (PR Newswire: ) (PR Newswire: ) That is why the real decision for payers and human resources teams is starting to look less like “Do we cover Wegovy or Zepbound?” and more like “What pathway does a patient follow before, during, and after treatment?” Employers interviewed by Peterson-KFF said use was higher than expected and significantly increased prescription drug costs, which makes step therapy, coaching, side-effect management, and off-ramps harder to avoid. (Peterson-KFF Health System Tracker: ) Business Group on Health reported that projected employer health care cost trend for 2025 rose to almost 8 percent, the highest level in more than a decade, with expensive drugs such as glucagon-like peptide-1 treatments among the pressures. When pharmacy spending is already taking a bigger share of the budget, every obesity treatment decision starts to look like a plan design decision, not just a clinical one. (Business Group on Health: ) Both new surveys come from companies with a stake in how obesity care is delivered